Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P377: Evaluation of the pharmacokinetic profiles of SB5 and reference adalimumabECCO '17 Barcelona
Year: 2017
Authors:

Shin D.1, Kang J.W.2, Park S.2, Cheong S.Y.1, Hong E.*1

1Samsung Bioepis Co., Ltd, Medical Team, Incheon, South Korea 2Samsung Bioepis Co., Ltd, Quality Evaluation Team, Incheon, South Korea

P378: Renal AA amyloidosis associated with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Bibani N., Gharbi O., Trad D., Sabbah M., Ouakaa A., Gargouri D., Elloumi H., Kharrat J.

Gastroenterology, Hospital of Habib Thameur, Tunis, Tunisia

P379: Is febuxostat the solution for patients who develop side effects to low dose azathioprine and allopurinol co-therapy?ECCO '17 Barcelona
Year: 2017
Authors:

Johnson H., Wade K., Hovell C., Weaver S., McLaughlin S.

Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

P380: Assessment of the awareness and education of vaccination in our IBD cohort: an observational studyECCO '17 Barcelona
Year: 2017
Authors:

Maheshwari P., Palaniappan S.K., Moran C., Forry M., Parihar V., Hall B., Reilly M., O'Toole A.

Beaumont Hospital Dublin, Gastroenterology, Dublin, Ireland

P381: Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Panaccione R.*1, Rutgeerts P.2, Sandborn W.3, Schreiber S.4, Colombel J.-F.5, Berg S.6, Maa J.-F.7, Petersson J.7, Robinson A.M.7

1University of Calgary, Department of Medicine, Calgary, Canada 2University of Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 3University of California San Diego, Division of Gastroenterology, La Jolla, United States 4University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany 5Icahn School of Medicine at Mount Sinai, New York, United States 6AbbVie AB, Solna, Sweden 7AbbVie Inc., North Chicago, United States

P382: A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

de Bruyn M.*1,2, Ringold R.3, Ferrante M.2,4, Van Assche G.2,4, Opdenakker G.1, Dukler A.3, Vermeire S.2,4

1Rega Institute for Medical Research, KU Leuven, Department of Microbiology and Immunology, Laboratory of Immunobiology, Leuven, Belgium 2KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium 3Kepler Diagnostics, Inc., Simi Valley, CA, United States 4University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

P383: Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in CanadaECCO '17 Barcelona
Year: 2017
Authors:

Marshall J.K.*1,2, Marrache A.M.3, Ewara E.4

1McMaster University Medical Center, Department of Gastroenterology, Hamilton, Canada 2Farncombe Family Digestive Health Research Institute, Hamilton, Canada 3Janssen Inc., Medical Affairs, Toronto, Canada 4Janssen Inc., Government Affairs and Market Access, Toronto, Canada

P384: Long-term outcome and endoscopic healing rates following long modified side-to-side strictureplastiesECCO '17 Barcelona
Year: 2017
Authors:

Van Stappen J.*1, De Buck van Overstraeten A.2, Ferrante M.1, Vanbeckevoort D.3, Van Assche G.1, D'Hoore A.2, Vermeire S.1

1University Hospitals Leuven, Gastroenterology, Leuven, Belgium 2University Hospitals Leuven, Abdominal surgery, Leuven, Belgium 3University Hospitals Leuven, Radiology, Leuven, Belgium

P385: Assessment of long-term outcomes of patients with ulcerative colitis and mucosal healing under different therapies: Is all mucosal healing the same?ECCO '17 Barcelona
Year: 2017
Authors:

Raimundo Fernandes S.*1, Correia L.1, Baldaia C.2, Moura Santos P.2, Rita Gonçalves A.2, Valente A.2, Velosa J.1

1Hospital de Santa Maria, Serviço de Gastrenterologia e Hepatologia, Lisboa, Portugal 2Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

P386: A target 6-thioguanine nucleotide ≥125 is associated with a higher rate and longer durability of response in infliximab–thiopurine combination therapy: a retrospective study in Crohn's disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Luber R.*1,2, Kariyawasam V.3, Dawson L.1, Munari S.1, Gibson P.1,2, Sparrow M.1,2, Ward M.1,2

1The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia 2Monash University, Melbourne, Australia 3University of Western Sydney, Department of Gastroenterology, Sydney, Australia

P387: The addition of an immunosuppressant is an effective optimization strategy after loss of response to anti-TNF-alpha monotherapy in patients with inflammatory bowel disease: a two-year experienceECCO '17 Barcelona
Year: 2017
Authors:

Macaluso F.S., Sapienza C., Ventimiglia M., Renna S., Rizzuto G., Orlando R., Affronti M., Orlando E., Cottone M., Orlando A.

Division of Internal Medicine, “Villa Sofia-Cervello” Hospital, Palermo, Italy

P388: Risk of relapse in ulcerative colitis patients in clinical remission with combination therapy (anti-TNF and azathioprine) after immunomodulator discontinuationECCO '17 Barcelona
Year: 2017
Authors:

Mihai C., Dranga M., Gavrilescu O., Ungureanu I., Didita A., Chiosa A.M., Savin A., Popa I., Popa R., Jigaranu O., Cijevschi-Prelipcean C.

University of Medicine and Pharmacy, Department of Gastroenterology, Iasi, Romania

P389: Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn's disease after ileal resectionECCO '17 Barcelona
Year: 2017
Authors:

Glick L.*1, Sossenheimer P.H.1, Hirsch A.1, Hurst R.D.2, Cohen R.D.1, Hyman N.2, Rubin D.T.1

1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States 2University of Chicago Medicine, Department of Surgery, Chicago, United States

P390: Open-label study to evaluate the pharmacokinetics of fidaxomicin in inflammatory bowel disease patients with Clostridium difficile infection (the PROFILE study): pharmacokinetics analysisECCO '17 Barcelona
Year: 2017
Authors:

Högenauer C.1, Mahida Y.2, Stallmach A.3, Marteau P.4, Rydzewska G.5, Ivashkin V.6, Gargalianos-Kakolyris P.7, Michon I.8, Adomakoh N.9, Reinisch W.*10

1Medical University of Graz, Graz, Austria 2University of Nottingham, Nottingham, United Kingdom 3Jena University Hospital, Jena, Germany 4Hôpital Saint Antoine, Paris, France 5Central Clinical Hospital of the Ministry of the Interior, Warsaw and Jan Kochanowski University, Kielce, Poland 6'First Moscow State Medical University named after I.M. Sechenov' of the Ministry of Health of Russian Federation, Moscow, Russian Federation 7General Hospital of Athens “G. Gennimatas”, Athens, Greece 8Astellas Pharma Europe, Leiden, Netherlands 9Astellas Pharma, Chertsey, United Kingdom 10Medical University of Vienna, Vienna, Austria

P391: Differential use of vedolizumab in ulcerative colitis and Crohn's disease. Real life results from 2 tertiary referral centres in the United KingdomECCO '17 Barcelona
Year: 2017
Authors:

Kamperidis N.*1, Cavazza A.2, Wahed M.2, Arebi N.1

1St Mark's Hospital, London, United Kingdom 2Chelsea and Westminster Hospital, Gastroenterology, London, United Kingdom

P392: Comparison of dietary nutrient and food additive intake between patients with moderately active ulcerative colitis, healthy stool donors and the general Australian populationECCO '17 Barcelona
Year: 2017
Authors:

Costello S.*1,2,3, Mashei C.3, Bryant R.2,3, Katsikeros R.3, Waters O.4, Makanyanga J.4, Hughes P.2, Conlon M.5, Roberts-Thomson I.1,2, Andrews J.2,3

1The Queen Elizabeth Hospital, Gastroenterology, Woodville, Australia 2University of Adelaide, School of Medicine, Adelaide, Australia 3The Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia 4Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia 5CSIRO, Health and Biosecurity, Adelaide, Australia

P393: Evaluation of pharmacokinetic profiles of SB2 as a biosimilar of reference infliximabECCO '17 Barcelona
Year: 2017
Authors:

Shin D., Kang J.W., Park S., Lee Y., Lee S.

Samsung Bioepis Co., Ltd., Incheon, South Korea

P394: Prolonged azathioprine treatment reduces the need for surgery in early Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Qiu Y.*1, Mao R.1, Zhang S.-h.2, Feng R.2, Zeng Z.-r.1, Chen M.-h.2

1The first affiliated hospital of Sun-yat Sen University, Gastroenterology, Guangzhou, China 2The first affiliated hospital of Sun-yat Sen University, Guangzhou, China

P395: Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS)ECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Schreiber S.2, Tang M.T.3, Tatro A.R.3, Oh Y.S.*3, Maciuca R.3

1University of California, San Diego, La Jolla, United States 2Kiel University, Kiel, Germany 3Genentech, South San Francisco, United States

P396: Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Lefevre C., Fotsing G., Wangermez M., Beau P.

CHU Poitiers, Poitiers, France